Quest Diagnostics Files 8-K on Financials and Events

Ticker: DGX · Form: 8-K · Filed: 2025-01-30T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations, corporate-events

Related Tickers: DGX

TL;DR

Quest Diagnostics dropped an 8-K detailing financials and other events. Check it out.

AI Summary

Quest Diagnostics Inc. filed an 8-K on January 30, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes financial statements and exhibits. The company was formerly known as Corning Clinical Laboratories Inc. before changing its name on September 3, 1996.

Why It Matters

This filing provides an update on Quest Diagnostics' financial performance and significant corporate events, which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing providing information on financial results and corporate events, not indicating any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Quest Diagnostics Inc.'s results of operations and financial condition, as well as other events, and to include financial statements and exhibits.

When was this 8-K filed?

This 8-K was filed on January 30, 2025.

What was Quest Diagnostics Inc. formerly known as?

Quest Diagnostics Inc. was formerly known as Corning Clinical Laboratories Inc.

When did the company change its name from Corning Clinical Laboratories Inc.?

The company changed its name from Corning Clinical Laboratories Inc. on September 3, 1996.

What is the principal executive office address for Quest Diagnostics Inc.?

The principal executive office address for Quest Diagnostics Inc. is 500 Plaza Drive, Secaucus, NJ 07094.

From the Filing

0001022079-25-000008.txt : 20250130 0001022079-25-000008.hdr.sgml : 20250130 20250130064703 ACCESSION NUMBER: 0001022079-25-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250130 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250130 DATE AS OF CHANGE: 20250130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 25571124 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx-20250130.htm 8-K dgx-20250130 0001022079 false 0001022079 2025-01-30 2025-01-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) : January 30, 2025 Quest Diagnostics Inc orporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.) 500 Plaza Drive Secaucus, NJ 07094 (Address of principal executive offices) (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition On January 30, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.      Item 8.01. Other Events On January 30, 2025, the Company announced that its Board of Directors had authorized a 6.7% increase in its quarterly dividend from $0.75 to $0.80 per share, or $3.20 per share annually, effective with the dividend payable on April 21, 2025 to shareholders of record of Quest Diagnostics Incorporated common stock on April 7, 2025. The Company has raised its dividend annually since

View on Read The Filing